Details of the Drug Combinations

General Information of This Drug (ID: DMLB81S)

Drug Name
Paclitaxel   DMLB81S
Synonyms
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-b; 7-epi-Paclitaxel; ABI-007; Abraxane; Capxol; Ebetaxel; EmPAC; Genaxol; Genetaxyl; Genexol; Intaxel; LipoPac; OncoGel; Onxol; Paclitaxel (Taxol); Paxceed; Paxene; Plaxicel; TAXOL; TaxAlbin; Taxol A; Xorane; Yewtaxan; Zisu; nab-paclitaxel; paclitaxel
Indication
Disease Entry ICD 11 Status REF
Breast carcinoma N.A. Approved [1]
Cutaneous melanoma 2C30 Approved [1]
Cutaneous squamous cell carcinoma 2C30 Approved [1]
Epithelial ovarian cancer 2B5D Approved [1]
Extragonadal germ cell tumor N.A. Approved [1]
Fallopian tube neoplasm N.A. Approved [1]
Gastroesophageal junction adenocarcinoma 2B71 Approved [1]
Inflammatory breast cancer 2C62 Approved [1]
Kaposi sarcoma 2B57 Approved [1]
Lung adenocarcinoma N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Ocular hypertension 9C61.01 Approved [1]
Ovarian neoplasm N.A. Approved [1]
Ovarian serous cystadenocarcinoma N.A. Approved [1]
Pain MG30-MG3Z Approved [1]
Pancreatic ductal carcinoma 2C10.0 Approved [1]
Primary peritoneal carcinoma N.A. Approved [1]
Testicular germ cell tumor N.A. Approved [1]
Urethral cancer 2C93 Approved [1]
Lung large cell carcinoma N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Carboplatin + Paclitaxel DCUP0OH Carboplatin Lung cancer (Cell Line: .) [2]
OGX-427 + Paclitaxel DCTMFNE OGX-427 Lung cancer; Prostate cancer; Bladder cancer; Ovarian cancer; Breast cancer (Cell Line: .) [3]
Paclitaxel + Oblimersen DC5EN3P Oblimersen Small-cell lung cancer (Cell Line: .) [4]
------------------------------------------------------------------------------------
65 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Bryostatin-1 + Paclitaxel DCGO6HS Bryostatin-1 Esophageal Cancer [5]
Buparlisib + Paclitaxel DCMXPBN Buparlisib Breast Cancer [6]
Carboplatin + Paclitaxel DCKUBDT Carboplatin Adenocarcinoma of the Lung [7]
Carboplatin + Paclitaxel DCOI26E Carboplatin Lung Cancer [8]
Carboplatin + Paclitaxel DC1GYK7 Carboplatin Cancer of Cervix [9]
Carboplatin + Paclitaxel DC3HXFI Carboplatin Carcinoma, Non-Small-Cell Lung [10]
Carboplatin + Paclitaxel DC5SIEV Carboplatin Cancer [11]
Carboplatin + Paclitaxel DC88YCK Carboplatin Non-Small Cell Lung Cancer [12]
Carboplatin + Paclitaxel DCA8U3B Carboplatin Ovarian Sarcoma [13]
Carboplatin + Paclitaxel DCC3X45 Carboplatin HIV Infection [14]
Carboplatin + Paclitaxel DCGAKVT Carboplatin Unspecified Adult Solid Tumor, Protocol Specific [15]
Carboplatin + Paclitaxel DCM5G2L Carboplatin Endometrial Cancer [16]
Carboplatin + Paclitaxel DCVAU54 Carboplatin Unspecified Adult Solid Tumor, Protocol Specific [17]
Carboplatin + Paclitaxel DCYLUJZ Carboplatin Tumors [18]
Cycloleucine + Paclitaxel DC8G0PS Cycloleucine Esophageal Cancer [19]
Cyclophosphamide + Paclitaxel DC4X6FF Cyclophosphamide Stage IA Breast Cancer [20]
Cyclophosphamide + Paclitaxel DCHXAOZ Cyclophosphamide Breast Cancer [21]
Erlotinib + Paclitaxel DCRZOWJ Erlotinib Unspecified Adult Solid Tumor, Protocol Specific [22]
Gemcitabine + Paclitaxel DCUMAK5 Gemcitabine Head and Neck Cancer [23]
HKI-272 + Paclitaxel DC8WXKO HKI-272 Breast Cancer [24]
Isotretinoin + Paclitaxel DCYIJUX Isotretinoin Lung Cancer [25]
Lenalidomide + Paclitaxel DC1KTN6 Lenalidomide Prostate Cancer [26]
Lovastatin + Paclitaxel DCVR76N Lovastatin Ovarian Cancer [27]
Napabucasin + Paclitaxel DCWM28L Napabucasin Oncology [28]
Olaparib + Paclitaxel DC28REP Olaparib Breast Cancer [29]
Olaparib + Paclitaxel DCRIHT1 Olaparib Gastric Cancer [30]
Paclitaxel + Epirubicin DCG4V5F Epirubicin Metastatic Breast Cancer [31]
Paclitaxel + Epirubicin DC2I73T Epirubicin Metastatic Breast Cancer [31]
Paclitaxel + Estramustine DC2MVWS Estramustine Prostate Cancer [32]
Paclitaxel + ABT-263 DC9W36D ABT-263 Solid Tumors [33]
Paclitaxel + Suramin DCDCQ4Y Suramin Recurrent Breast Cancer [34]
Paclitaxel + Bortezomib DCGF04P Bortezomib Unspecified Adult Solid Tumor, Protocol Specific [35]
Paclitaxel + Vorinostat DCL4C98 Vorinostat Male Breast Cancer [36]
Paclitaxel + Vorinostat DCTOJ2D Vorinostat Stage IIIA Non-small Cell Lung Cancer [37]
Paclitaxel + Oxaliplatin DCUC9D5 Oxaliplatin Cervical Adenocarcinoma [38]
Paclitaxel + Tanespimycin DCUF85X Tanespimycin Unspecified Adult Solid Tumor, Protocol Specific [39]
Paclitaxel + Imatinib DCVD20F Imatinib Non-small Cell Lung Cancer [40]
Paclitaxel + KX-01 DCYEUFH KX-01 Solid tumour/cancer [41]
Paclitaxel + Rocilinostat DCSMG3I Rocilinostat Ovarian Cancer [42]
Pazopanib + Paclitaxel DCFLA2D Pazopanib Bladder Cancer [43]
PMID25656651-Compound-7 + Paclitaxel DC4FEFD PMID25656651-Compound-7 Breast Cancer [44]
Rivoceranib + Paclitaxel DCDRO2D Rivoceranib Gastric Cancer [45]
Ruxolitinib + Paclitaxel DC0HHXQ Ruxolitinib Recurrent Breast Cancer [46]
VS-6063 + Paclitaxel DCJ18GF VS-6063 Ovarian Cancer [47]
AZD5363 + Paclitaxel DCTYZ09 AZD5363 Metastatic Breast Cancer [48]
Carboplatin + Paclitaxel DC040OJ Carboplatin Lung Cancer [49]
Carboplatin + Paclitaxel DC38483 Carboplatin Ciliary Body and Choroid Melanoma, Medium/Large Size [50]
Carboplatin + Paclitaxel DCGC4XT Carboplatin Stage IIIB or IV Non-Small Cell Lung Cancer [51]
Carboplatin + Paclitaxel DCJN8ZV Carboplatin Recurrent Non-small Cell Lung Cancer [52]
Carboplatin + Paclitaxel DCLVC7T Carboplatin Non-small Cell Lung Cancer [53]
Carboplatin + Paclitaxel DCVZVCR Carboplatin Ovarian Neoplasms [54]
Carboplatin + Paclitaxel DCXBPQG Carboplatin Non-Small Cell Lung Cancer [55]
Carboplatin + Paclitaxel DCMY3HT Carboplatin Non-small-cell Lung Cancer [56]
Efatutazone + Paclitaxel DC9S3OU Efatutazone Anaplastic Thyroid Cancer [57]
MK-1775 + Paclitaxel DCKW17N MK-1775 Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation [58]
Nedaplatin + Paclitaxel DC0A5RR Nedaplatin Esophageal Neoplasms [59]
Paclitaxel + Pentoxifylline DC0JLGT Pentoxifylline Breast Cancer Female [60]
Paclitaxel + MLN8237 DC21IJH MLN8237 Bladder Cancer [61]
Paclitaxel + MLN8237 DCFHV22 MLN8237 Breast Cancer [62]
Paclitaxel + Capecitabine DCJ59FN Capecitabine Breast Cancer [63]
Paclitaxel + Capecitabine DCMC8M0 Capecitabine Gastric Adenocarcinoma [64]
Paclitaxel + Afatinib DCUV0R0 Afatinib HER-2 Positive Gastric Cancer [65]
Pazopanib + Paclitaxel DCUEB5Z Pazopanib Ovarian Cancer [66]
Rivoceranib + Paclitaxel DCHHL3X Rivoceranib Triple Negative Breast Cancer [67]
Docetaxel + Paclitaxel DC8P2TD Docetaxel Locally Advanced or Metastatic Unresectable Urothelial Cancer [68]
------------------------------------------------------------------------------------
⏷ Show the Full List of 65 DrugCom(s)

References

1 Paclitaxel FDA Label
2 Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55.
3 FDA Drug Development and Drug Interactions
4 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
5 ClinicalTrials.gov (NCT00006081) Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
6 ClinicalTrials.gov (NCT01572727) A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
7 ClinicalTrials.gov (NCT00002852) Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
8 ClinicalTrials.gov (NCT00004859) Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
9 ClinicalTrials.gov (NCT02312804) Ph Ib/BGJ398/Cervix and Other Solid Tumors
10 ClinicalTrials.gov (NCT00539331) Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients
11 ClinicalTrials.gov (NCT01000896) Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
12 ClinicalTrials.gov (NCT01225302) A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
13 ClinicalTrials.gov (NCT00408655) Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
14 ClinicalTrials.gov (NCT01249443) Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
15 ClinicalTrials.gov (NCT00028587) PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
16 ClinicalTrials.gov (NCT01256268) Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
17 ClinicalTrials.gov (NCT00287937) Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
18 ClinicalTrials.gov (NCT00201734) Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
19 ClinicalTrials.gov (NCT00033657) Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
20 ClinicalTrials.gov (NCT01106898) Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
21 ClinicalTrials.gov (NCT03356860) Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
22 ClinicalTrials.gov (NCT00042809) Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
23 ClinicalTrials.gov (NCT00100789) S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
24 ClinicalTrials.gov (NCT00915018) Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
25 ClinicalTrials.gov (NCT00062010) Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
26 ClinicalTrials.gov (NCT00933426) Lenalidomide and Paclitaxel in Prostate Cancer
27 ClinicalTrials.gov (NCT00585052) A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
28 ClinicalTrials.gov (NCT04299880) Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
29 ClinicalTrials.gov (NCT00707707) Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
30 ClinicalTrials.gov (NCT01063517) Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
31 ClinicalTrials.gov (NCT01433614) Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer
32 ClinicalTrials.gov (NCT00038168) Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
33 ClinicalTrials.gov (NCT00891605) Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
34 ClinicalTrials.gov (NCT00054028) Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
35 ClinicalTrials.gov (NCT00030368) Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
36 ClinicalTrials.gov (NCT00368875) Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
37 ClinicalTrials.gov (NCT00662311) Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
38 ClinicalTrials.gov (NCT00057863) Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
39 ClinicalTrials.gov (NCT00087217) 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
40 ClinicalTrials.gov (NCT01011075) Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
41 Clinical pipeline report, company report or official report of Kinex Pharmaceuticals.
42 ClinicalTrials.gov (NCT02661815) A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
43 ClinicalTrials.gov (NCT01108055) Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
44 ClinicalTrials.gov (NCT02824575) Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
45 ClinicalTrials.gov (NCT03707028) Safety, Tolerability and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced GC or GEJ Cancer.. U.S. National Institutes of Health.
46 ClinicalTrials.gov (NCT02041429) Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
47 ClinicalTrials.gov (NCT01778803) Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
48 ClinicalTrials.gov (NCT02423603) PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
49 ClinicalTrials.gov (NCT00290537) Phase II Study of ZD6474 in Advanced NSCLC
50 ClinicalTrials.gov (NCT00288041) Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
51 ClinicalTrials.gov (NCT00473889) A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
52 ClinicalTrials.gov (NCT00006929) Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
53 ClinicalTrials.gov (NCT01649947) Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
54 ClinicalTrials.gov (NCT00610714) AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
55 ClinicalTrials.gov (NCT02591615) Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
56 ClinicalTrials.gov (NCT01836679) Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer
57 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
58 ClinicalTrials.gov (NCT02272790) Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
59 ClinicalTrials.gov (NCT02858206) Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
60 ClinicalTrials.gov (NCT05189535) "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
61 ClinicalTrials.gov (NCT02109328) Alisertib in Chemotherapy-pretreated Urothelial Cancer
62 ClinicalTrials.gov (NCT02187991) Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
63 ClinicalTrials.gov (NCT02474186) Phase II Study for Solid Metastatic Tumors
64 ClinicalTrials.gov (NCT04034251) Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
65 ClinicalTrials.gov (NCT02274012) Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
66 ClinicalTrials.gov (NCT02383251) Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer
67 ClinicalTrials.gov (NCT03348098) Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer
68 ClinicalTrials.gov (NCT04527991) Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer